Patents by Inventor Ivan Jabin

Ivan Jabin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230101856
    Abstract: This invention concerns a versatile and simple one-pot method to prepare nanomaterials, and in particular nanoparticles, grafted with an ultra-thin layer of calixarenes by placing at 5 least one oxidized metal with at least one calix[n]arene diazonium salt in the presence of a reducing agent in a solvent, and heating the traction mixture to obtain a metal-based nanomaterial coated with calix[n]arenes. The invention further concerns the coupling of organic molecules or biomolecules to the calixarene-grafted nanomaterials in order to further functionalize the surface of the particles. The metal-based nanomaterial coated with 10 calix[n]arenes can for example be used in immunoassays.
    Type: Application
    Filed: February 10, 2021
    Publication date: March 30, 2023
    Applicant: UNIVERSITE LIBRE DE BRUXELLES
    Inventors: Gilles BRUYLANTS, Ivan JABIN, Maurice RETOUT, Bryan GOSSELIN
  • Patent number: 11124617
    Abstract: This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: September 21, 2021
    Assignees: UNIVERSITE LIBRE DE BRUXELLES (ULB), CENTER NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE RENNES 1, UNIVERSITE DE PARIS
    Inventors: Ivan Jabin, Alice Mattiuzzi, Corinne Lagrost, Philippe Hapiot, Olivia Reinaud
  • Publication number: 20190233358
    Abstract: This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process.
    Type: Application
    Filed: April 4, 2019
    Publication date: August 1, 2019
    Applicants: UNIVERSITE LIBRE DE BRUXELLES (ULB), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DESCARTES
    Inventors: Ivan JABIN, Alice MATTIUZZI, Corinne LAGROST, Philippe HAPIOT, Olivia REINAUD
  • Patent number: 10329232
    Abstract: A calixarene directly grafted onto the surface of a material, a related grafting process, and certain calixarene intermediates useful for carrying out the grafting process.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: June 25, 2019
    Assignees: UNIVERSITE LIBRE DE BRUXELLES (ULB), CENTER NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE DE RENNES 1, UNIVERSITE PARIS DESCARTES
    Inventors: Ivan Jabin, Alice Mattiuzzi, Corlnne Lagrost, Philippe Hapiot, Olivia Reinaud
  • Publication number: 20150064455
    Abstract: This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 5, 2015
    Inventors: Ivan Jabin, Alice Mattiuzzi, Corlnne Lagrost, Philippe Hapiot, Olivia Reinaud
  • Patent number: 6255324
    Abstract: 5′-substituted, 4′,5′-dihydropsoralen compounds (5) bearing tertiary amines (and salts thereof), quaternary ammonium moieties or organomercurial moieties are described. Also described are 2-substituted mercurimethyl-2-3-dihydro-benzofurans of forumla (7): Also reported are versatile direct syntheses through a hitherto unknown compounds such as 3-R-4,8-dimethyl-4′,5′-dihydro-5′-bromomethylpsoralen or a 3-R-4,8-dimethyl-4′, 5′-dihydro-5′-iodomethylpsoralen to prepare a structurally diverse array of partially reduced psoralens and benzofurans. The presence of a permanent ammonium charge in these psoralens precludes membrane passage and the mono-unsaturation precludes the cross-linking of nuclear DNA, thereby minimizing the mutagenic/carcinogenic side effects long associated with psoralen-derived therapies.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: July 3, 2001
    Inventors: Ned D. Heindel, Jeffrey D. Laskin, Diane E. Heck, Robert D. Rapp, Marilyn S. Whittemore, Thomas E. McNeel, Ivan Jabin